Roger A. Jeffs, Ph.D., serves as Chief Executive Officer of Liquidia Corporation, a biopharmaceutical company pioneering the development and commercialization of therapies utilizing its proprietary PRINT® particle engineering platform. With more than 25 years of leadership in the biopharmaceutical industry, Dr. Jeffs brings extensive expertise in drug development, regulatory strategy, and commercialization, particularly in rare pulmonary diseases. He assumed the CEO role at Liquidia in 2020, guiding the company through pivotal milestones, including the advancement of its lead product, YUTREPIA™ (treprostinil) inhalation powder, toward FDA approval for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Prior to Liquidia, Dr. Jeffs was President and Chief Executive Officer of United Therapeutics Corporation from 2005 to 2020, where he spearheaded the company's transformation into a global leader in PAH treatments. Under his leadership, United Therapeutics achieved multiple FDA approvals for innovative therapies, including Remodulin®, Tyvaso®, and Orenitram®, significantly expanding treatment options and growing the company's market capitalization from under $1 billion to over $10 billion. His strategic vision also fostered advancements in organ manufacturing and telemedicine, solidifying United Therapeutics' position at the forefront of biotechnology innovation. Dr. Jeffs earned his Ph.D. in Pharmacology from the University of Michigan and a B.S. in Pharmacy from the University of North Carolina at Chapel Hill. At Liquidia, he continues to leverage his deep industry knowledge to enhance the company's pipeline, emphasizing inhaled therapies that improve patient outcomes and address unmet needs in cardiopulmonary medicine.